The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Purpose Bitcoin ETF
BTCC:CA
Silver47 Exploration
AGA:CC
Syntheia
SYAI:CC
Black Swan Graphene
SWAN:CC
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Roche's Research Capabilities and Smart Pricing Offer an Advantage in the Pharmaceutical Market
Jul. 27, 2015 09:30AM PST
Pharmaceutical InvestingFollowing the news that Roche Holdings (OTCMKTS:RHHBY) saw a 6% increase in revenues in the second quarter, Forbes assessed why Roche Holdings continues to grow while other pharmaceutical companies are limited by the impact of the patent cliff.
Following the news that Roche Holdings (OTCMKTS:RHHBY) saw a 6% increase in revenues in the second quarter, Forbes assessed why Roche Holdings continues to grow while other pharmaceutical companies are limited by the impact of the patent cliff.
According to the article:
We believe Roche’s success is an amalgamation of strong research capabilities and smart pricing, which is all that’s needed to compete in the global pharmaceutical market. We see little downside to the stock considering Roche’s recent financial performance, its focus on broadly growing areas of oncology and immunology, and bubbling R&D pipeline. We are in the process of updating our price estimate for Roche Holdings in light of recent earnings and will have an update ready soon.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.